Predicting Treatment Cost for Bacterial Diarrhoeaat a Regional Hospital in Thailand* by Riewpaiboon, Arthorn et al.
©INTERNATIONAL CENTRE FOR DIARRHOEAL
DISEASE RESEARCH, BANGLADESH
J HEALTH POPUL NUTR  2008 Dec;26(4):442-450
ISSN 1606-0997 | $ 5.00+0.20
Correspondence and reprint requests should be 
addressed to:
Dr. Arthorn Riewpaiboon
Associate Professor
Division of Social and Administrative Pharmacy
Department of Pharmacy, Faculty of Pharmacy
Mahidol University 
447 Sri Ayutthaya Road, Ratchathevi
Bangkok 10400 
Thailand  
Email: pyarp@mahidol.ac.th
Fax: 662 644 8694   
INTRODUCTION
Thailand is a Southeast Asian country with a popu-
lation of 62.4 million in 2005. Acute diarrhoea is 
one of the most prevalent diseases in Thailand, and 
morbidity rate pertaining to this disease has been 
ranked the highest in the country since 1985. Re-
sults of an epidemiological study in four hospitals 
in 2005 indicated that most diarrhoea patients were 
children aged less than five years (35.2%). Salmo-
nella spp. (39.9%), Vibrio parahaemolyticus (33.1%), 
Escherichia coli (18.0%), Shigella spp. (2.5%), and 
Vibrio cholerae El Tor Inaba (1.8%) were mainly re-
sponsible for the disease (1). The number of inpa-
tients at government hospitals (80.5% of the total 
hospital-beds in the country in 2004) was 11,323.8 
per 100,000 in 2004. Meanwhile, the numbers of in-
patients suffering from typhoid, paratyphoid fever, 
and other Salmonella-associated infections, includ-
ing other intestinal infectious diseases, was 629.7 
per 100,000 people. Ninety-six deaths due to acute 
diarrhoea and enteric fever were reported in 2004 
(2). This study was conducted as part of the project 
titled “Institutional cost of shigellosis in Kaengkhoi 
district, Saraburi province, Thailand.” The project is 
a part of the multi-country programme sponsored 
by the International Vaccine Institute, South Korea. 
Therefore, we would like to focus on bacterial diar-
rhoea to compare with shigellosis.
The major health-service facilities in Thailand, in 
terms of the number of settings and beds, are pub-
lic hospitals consisting of 725 district hospitals, 
70 provincial hospitals, and 25 regional hospitals 
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(3). The healthcare system of Thailand comprises 
three health insurance options: the Social Security 
Scheme (SSS) for private employees, the Civil Ser-
vant Medical Benefit Scheme (CSMBS) for govern-
ment employees, and the Universal Health Care 
Scheme (UC) for the remainder of the Thai people. 
The UC covers approximately two-thirds of the Thai 
population. The payment methods for hospitals 
are capitation (a fixed amount per person) for the 
SSS and the UC and fee-for-service for the CSMBS.   
The major revenue of the public hospitals comes 
from capitation. Due to public fiscal constraints 
and other reasons, the Government has not always 
approved the capitation rate requested (4). Thus, 
one of the important management moves in this 
situation is cost-containment (5). Correspondingly, 
it is pivotal for hospital administrators to know the 
cost of treatment, including factors that contribute 
to this cost, and to use such information for pru-
dent financial management. Hospital cost-analysis 
and cost-of-illness studies were introduced in Thai-
land less than a decade ago. And, in fact, a few hos-
pitals have conducted such research. In this light, 
the present study is aimed at analyzing the health 
costs of bacterial diarrhoea at a regional hospital 
(Saraburi Hospital) in central Thailand. Although 
the study was conducted in one hospital only, it is 
based on the concept of ‘better than nothing’.  
MATERIALS AND METHODS
This incidence-based cost-of-illness study was con-
ducted from a hospital (provider) perspective, em-
ploying a bottom-up or micro-costing approach 
(6). This study design measures the economic bur-
den on patients from the starting to the end-points 
of their illnesses. It observes only new cases occur-
ring within a given period and monitors them un-
til reaching the end-point. Since the study sites are 
public hospitals, the study may be categorized as 
being from a health system perspective or public 
perspective.
Cost of illness is composed of direct medical 
costs, direct non-medical costs, and indirect 
costs. Direct medical costs are healthcare-related 
costs directly spent for the prevention, detec-
tion, treatment, continuing care, rehabilitation, 
and terminal care of patients. This study covers 
only direct medical costs or treatment costs. In a 
bottom-up approach, costs are collected directly 
from a patient sample covering individual drug-
use and medical services. Medical services in-
clude outpatient (routine service) and inpatient 
services (food, hotel, and routine nursing care), 
drug-dispensing service, and laboratory investi-
gation service.
One public hospital—Saraburi Hospital—was se-
lected based on the availability of costing informa-
tion and cooperation of the hospital director and 
staff. The Saraburi Hospital is a 680-bed, regional 
tertiary-care hospital in Saraburi province, 108 km 
northeast of Bangkok. In the study year (2002), the 
hospital had 1,686 staff members, 1,100 outpatient 
visits per day, a bed-occupancy rate of 101.36% (in-
formal extra beds were provided), and an average 
length of hospitalization of 7.14 days.
The study subjects were newly-diagnosed bacterial 
diarrhoea patients who received treatment at the 
hospital during 1 October 2000–31 July 2003. The 
database on medical records of the hospital includes 
information on 878 outpatient and 233 inpatient 
cases. Patients were from all age-groups, of both 
sexes, and constituted both outpatients and inpa-
tients, with a definite diagnosis of diarrhoea clas-
sified according to the International Classification 
of Diseases (10th revision) (7) [Code A00-A05 defini-
tions in Table 1]. Some classifications were based 
on clinical symptoms. Generally, the diagnosis was 
based on physical examinations of outpatients and 
laboratory investigations of inpatients. Patients 
who were not discharged because of incomplete re-
covery, or had unimproved conditions in the final 
treatment, were excluded from the study.  
The sample size for cost-function analysis was based 
on the rule of at least 30 times the independent or 
potential predictor variables (8). Considering the 
factors affecting treatment cost, they were proposed 
based on a prescribing model. The factors were: 
health/hospital system, prescriber characteristics, 
and patient characteristics (9). Since the study was 
conducted in one hospital, only patient characteris-
tics were explored. From the hypothesis, there were 
12 independent variables, including dummy vari-
ables, so the minimum sample size was 360 cases. 
The variables included in the study were catego-
rized into demographic characteristics, i.e. age, gen-
der and health insurance schemes and clinical char-
acteristics, i.e. diagnosis and economic outcome 
(treatment cost). To collect data, the patients were 
drawn from the medical database of the hospital, and 
the medical records were then reviewed. To estab-
lish the economic outcomes, the amount of medi-
cal services received was multiplied by unit costs, 
which were, in turn, calculated at the 2002 prices.
The unit costs of medical services were calculated 
employing a standard costing approach (10,11). Riewpaiboon A et al. Predicting treatment cost for bacterial diarrhoea
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Table 1. Demographic and clinical characteristics of patients
Characteristics
 Frequency 
 (n=384 episodes)
Percentage
Female/male          216/168 56.3/43.7
Age (years) (mean=23.98 years)
  <5
  5-<15
  15-55 
  >55 
        90
        99
        149
        46
23.4
25.8
38.8
12.0
Type of service
  Inpatient episodes
  Outpatient episodes
        188
        196
49.0
51.0
Payment scheme
  Universal health coverage         130 33.9
  Out-of-pocket         117 30.5
  Civil Servant Medical Benefit Scheme          97 25.3
  Social Security Scheme         40 10.4
ICD code
  A00 Cholera
  A01 Typhoid and paratyphoid fevers
  A02 Other Salmonella infections
  A03 Shigellosis
  A04 Other bacterial intestinal infections
  A05 Other bacterial foodborne intoxications
        2
        2
        45
        31
        3
        301
0.5
0.5
11.7
8.1
0.8
78.4
This calculation consists of five steps: organiza-
tional analysis and cost centre classification, deter-
mination of direct cost, determination of indirect 
cost, determination of full cost, and calculation of 
the unit cost of medical services (12,13). The de-
partments of the hospital were categorized into 
105 patient-service or production cost centres, e.g. 
laboratory, pharmacy, outpatient, inpatient, and 52 
non-patient service or supporting cost centres, e.g. 
general administration, security, medical statistics, 
computer centre, and transportation. To qualify as 
a cost centre, an organizational unit must produce 
its own output and have a record of resource con-
sumption.
For the determination of direct cost of each cost 
centre, capital cost was computed as an equivalent 
annual economic cost (10,14) with a 3% discount 
rate as per the guidelines of the World Health Or-
ganization (15). The equivalent annual economic 
cost was defined as “an average combination of 
depreciation cost and interest on the undepreci-
ated portion over the useful life of the capital item” 
(16). The interest on the undepreciated portion of a 
capital item was calculated based on the concept of 
opportunity cost of money spent in advance for that 
portion. The interest was then calculated for the en-
tire useful life of the capital item and was discounted 
at the time of analysis. Useful life was considered 
to be five years and 20 years for capital items and 
buildings respectively (17,18). Indirect cost, which 
refers to the direct cost of supporting cost cen-
tres, was distributed to the production cost cen-
tres by the simultaneous allocation method (10). 
The simultaneous equation distribution emerges 
from an attempt to precisely calculate the cost-al-
location amounts. By this method, the interde-
partmental demands among the general services 
are more concerned with repeating the assignment 
of costs among the various cost centres to eliminate 
the residual costs in the general service departments. 
These infinite allocations are solved through setting 
simultaneous linear equations to establish the end 
of allocation—a method which provides the most 
accurate result. The services or outputs of supporting 
cost centres were then selected as allocation criteria, 
e.g. for the number of staff for the administration 
department. The average method and micro-cost-
ing of departmental allocation were employed for 
departments producing homogeneous and hetero-
geneous products respectively (19,20). Micro-costing 
is a means of allocating the cost of a production cost 
centre to each unit of service. The micro-costing 
method begins by valuing resources directly con-
sumed by each unit of service. Then the shared cost 
of the cost centre is allocated to the various services 
proportionally to their direct cost. Riewpaiboon A et al. Predicting treatment cost for bacterial diarrhoea
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To analyze the data, descriptive statistics were used 
for summarizing the study factors. Stepwise mul-
tiple regression analysis was employed to formu-
late the forecasting model of the treatment cost 
(21). Assumption and model diagnosis were also 
conducted (21-24). To analyze the uncertainty of 
results due to the sample data, one-way sensitivity 
analysis was used in this study. One-way sensitivity 
analysis is the method of using plausible values of 
uncertain factors for recalculating the results. The 
purchasing prices of drugs for hospital were includ-
ed in sensitivity analysis. 
RESULTS
Table 1 presents the demographic and clinical char-
acteristics of the patients. There were more females 
(56%) than males. The mean age of the patients 
was 24 years (median=16.5), and 48% of them were 
children aged less than 15 years. In terms of pay-
ment schemes, 34% of the patients were under the 
Universal Health Coverage Scheme. Seventy-eight 
percent of them were classified as ICD code A05 
(other bacterial intestinal foodborne intoxications).   
The unit costs of medical services and drug costs 
(purchasing prices of the hospital) are presented in 
Table 2. In total, 384 medical records or episodes 
(188 outpatients and 196 inpatients) were includ-
ed in the study. No patient was excluded because 
of unimproved discharge status. We found seven 
episodes with multiple visits and 17 patients with 
more than one episode during the study period. 
For inpatients, the average length of hospitaliza-
tion was 2.02 days (standard deviation=1.65).  
As presented in Table 3, treatment cost (direct med-
ical cost) comprised the costs of: outpatient service; 
hotel, or routine hospitalization service, i.e. room, 
meals, and routine medical and nursing care; labo-
ratory service; drug acquisition and dispensing; and 
medical materials. The average treatment cost of all 
patients (n=384 episodes) was US$ 44.72. Adjusting 
for the type of care, the average cost per episode 
of outpatient and inpatient care was US$ 11.29 
Table 2. Unit costs of some medical services and drugs at 2002 prices
Medical service Unit cost (US$)*
Average routine service in outpatient clinics (per visit)  4.06
Hospitalization; hotel cost with routine nursing care (per day)
  Average of internal medicine wards
  Average of paediatric wards
18.24
28.86
Stool examination 0.41
Routine stool culture 5.09
Culture for V. cholerae 3.90
Culture for Shigella species 3.60
Culture for Salmonella species 5.38
Haemoculture 4.53
Anaerobic culture 6.15
Complete blood count  1.61
Drug
Base-case–minimum/
maximum prices†
Norfloxacin 100 mg tablet 1.50-0.75/10.28   
Norfloxacin 400 mg tablet 2.45-1.40/5.75 
Ciprofloxacin 250 mg tablet 8.80-2.50/3.75
Domperidone tablet 0.78-0.25/1.05
Hyoscine-N-butyl bromide tablet  3.65-1.25/3.40
Metoclopramide 5 mg tablet 0.45-0.35/0.63
Paracetamol 500 mg tablet 0.30-0.20/0.80
ORS adult sachet 6.75-2.50/12.00
ORS paediatric sachet 4.25-2.38/9.00
5% dextrose in half-normal saline solution, 1,000 mL bag 40.00-37.33/63.75
Normal saline solution, 1,000 mL bag 41.25-34.75/149.75
*1 US$=40 Thai bath; †Price (each) per 100 units; ORS=Oral rehydration solution Riewpaiboon A et al. Predicting treatment cost for bacterial diarrhoea
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and US$ 76.78 respectively. The largest portion of 
these amounts was hotel cost which accounted for 
US$ 58.82 (77%) per inpatient episode. [These costs 
can be converted to the 2006 prices using the con-
sumer price index of Thailand (25). Prices increased 
from a base rate of 100 in 2002 to 114.4 in 2006.   
Hence, the average treatment cost was US$ 51.16 at 
the 2006 prices.]
To test the effect of the variation of drug costs or 
purchasing prices on the study results, the prices 
of the top 10 most frequently-used drugs and the 
top 10 most highly-priced drugs were included. 
For base-case analysis, the prices were taken from 
the normal purchasing records of the hospital. The 
prices for sensitivity analyses were those that were 
referred from the purchasing reports of hospitals 
under the Ministry of Public Health in fiscal year 
2002 (26). The top 10 most frequently-used drugs 
were: domperidone tablet; paracetamol 500 mg; 
hyoscine-N-butyl bromide tablet; norfloxacin 400 
mg; ORS (oral rehydration solution) adult; ORS pae-
diatric; norfloxacin 100 mg; metoclopramide 5 mg; 
5% dextrose in half-normal saline solution, 1,000 
mL; and ciprofloxacin 250 mg. The maximum and 
minimum prices of drugs were used in recalculat-
ing the total drug cost and total treatment cost. The 
results indicated significant changes in both drug 
and total treatment costs. When the minimum and 
maximum prices of drugs were used in recalcula-
tion, there were changes of -4.09% to 10.25%, and 
-0.31% to 0.79% for drug cost and treatment cost 
respectively. The top 10 most highly-priced drugs 
used for bacterial diarrhoea were:  cefotaxime 1 g; 
imipenam 500 mg; ceftriazone 1 g; 5% dextrose in 
half-normal saline solution, 1,000 mL; hyoscine-N-
butyl bromide injection; ciprofloxacin 0.1 g/50 mL; 
ranitidine 50 mg; 5% dextrose in 1/3 normal saline 
solution, 1,000 mL; cefpirom 1 g; and normal saline 
solution, 1,000 mL. The maximum and minimum 
prices of highly-priced drugs affected the total drug 
cost and the total treatment cost by -31.56% to 
29.13% and -2.42% to 2.24% respectively. These 
effects were greater than those of the top 10 most 
frequently-used drugs.  
To predict the treatment cost, the normal distribu-
tion of cost was tested. The results revealed that 
most costs were not normally distributed (27).   
Natural logarithms were then applied in the trans-
formation, and further assumption tests and model 
diagnoses were conducted as guidelines (21,22).   
The potential explanatory variables included in 
this analysis were:  gender, age-group, health insur-
ance status, and diagnostic group. The result of the 
multiple regression model is seen in the equation:
Lncost=5.932+1.572(Inpatient)+1.074(A02)+0.203 
(A03)+0.929(A04)+0.118 (CSMBS)
The adjusted R2 of the model was 0.831. This means 
that 83.1% of the variation in treatment cost could 
be predicted by the total variables in the model. 
The predictor variables were composed of: type of 
patient, i.e. inpatient; type of pathogen, i.e. other 
Salmonella infections [ICD code A02], shigellosis 
[ICD code A03], or other bacterial intestinal infec-
tions [ICD code A04]); and payment (insurance) 
scheme, i.e. CSMBS).
To estimate the expected response on an untrans-
formed scale after fitting a linear regression model 
of the transformed scale, it should be adjusted by 
a smearing factor (28,29). Table 4 shows the pre-
dicted treatment cost of patients with various con-
ditions. Patients with health insurance other than 
the CSMBS, who were infected by other bacterial 
Table 3. Average cost per episode (US$ at 2002 prices)
Service
Outpatient episodes
Cost (95% CI)
Inpatient episodes
Cost (95% CI)
Outpatient and inpa-
tient episodes
Cost (95% CI)
Outpatient care 5.25 (4.90-5.60) N/A N/A
Inpatient care  N/A 58.82 (51.05-66.60) N/A
(average LOS 2.02 days 
95% CI 1.79- 2.25)
Laboratory 0.41 (0.05-0.78) 7.92  (6.75-9.08) 4.24 (3.53-4.98)
Acquisition drug cost 0.86 (0.65-1.08) 3.95  (2.45-5.43) 2.44 (1.65-3.23 )
Drug dispensing cost 4.81 (4.48-5.15) 2.27 (2.00-2.55) 3.51 (3.25-3.78)
Medical material cost 0.08 (0.03-0.15) 1.78 (1.48-2.08) 0.95 (0.78-1.13)
Total cost 11.29 (10.38-12.20) 76.78 (66.65-86.90) 44.72 (38.60-50.85)
CL=Confidence interval; LOS=Length of stay; N/A=Not applicable Riewpaiboon A et al. Predicting treatment cost for bacterial diarrhoea
Volume 26 | Number 4 | December 2008 447
foodborne intoxications (A05) and who were treat-
ed as outpatients, had the lowest cost (US$ 10.27). 
Meanwhile, patients who were insured by the 
CSMBS, who had other Salmonella infections (A02) 
and were treated as inpatients, had the highest cost 
(US$ 162.87). 
DISCUSSION
Forty-seven percent of the study patients were aged 
less than 15 years. The mean age of the patients 
was 24 years, which was similar to the results of 
other studies, indicating that diarrhoea is more 
common in children (30). The hospitalization was 
relatively short (2.02 days), which can be explained 
by the fact that the study hospital is a general hos-
pital. There are some chronic and severe patients. 
Diarrhoea patients are usually admitted to receive 
intravenous fluid and are then discharged with oral 
antibiotics. This is done to use hospital-beds effi-
ciently.
Regarding identification of pathogens in terms of 
ICD code, 90% were identified to be Salmonella 
infections (A04) and other bacterial foodborne in-
toxications (A05). Patients with specifying patho-
gens (cholera–0,5%, typhoid–0.5%, and shigel-
losis–8.1%) were identified based on laboratory 
investigations at the hospital. This is because most 
outpatients were diagnosed based on clinical ex-
aminations and the experience of physicians. Stool 
culture takes a few days and, therefore, was not es-
pecially useful for the treatment of outpatients. In 
these situations, physicians provided empiric treat-
ment that was considered to be acceptable (31). It 
is possible that identification of some pathogens 
might increase if all cases had been tested by labora-
tory investigations. Therefore, this study has a limi-
tation in terms of identification of pathogens. In 
addition, there were no laboratory investigations to 
confirm the results of treatment of outpatients. We, 
thus, assumed that the patients had fully recovered. 
To support this assumption, the data showed that 
patients would come back to the hospital if they 
had not recovered as we found several multi-visit 
episodes.  
The average treatment cost of outpatients was rela-
tively high because this study encompassed total 
economic costs: capital costs, i.e. building, con-
struction, vehicle, equipment, and land; labour 
costs, such as salary, extra payments, and medical 
welfare; and material costs. The study also covered 
both direct cost of patient-care departments and 
indirect cost allocated from non-patient-care de-
partments. The inpatient cost appeared relatively 
low compared to that of outpatients, which can be 
explained based on the length of hospitalization.   
The average duration of inpatient hospitalization 
was only 2.02 days. Therefore, hotel cost (the cost 
of inpatient care) was not especially high, resulting 
in a low overall treatment cost (since hotel cost is 
a major part of the treatment cost and since the 
treatment cost is a result of unit cost of the services 
multiplied by quantity of the services received). 
Unit costs of this study are comparable with the 
hotel cost estimation of the WHO-CHOICE pro-
gramme (32). The WHO-CHOICE study estimated 
a cost of 1,000 Thai baht (at the 2000 prices) per 
patient-day in a tertiary hospital. However, based 
on this study, the costs are 729 and 1,154 Thai baht 
Table 4. Predicted treatment costs at 2002 prices
Type of patients Predicted treatment cost (US$)
Shigellosis (A03); non-CSMBS outpatient  12.58
Shigellosis (A03); non-CSMBS inpatient  60.58
Shigellosis (A03); CSMBS outpatient  14.15
Shigellosis (A03); CSMBS inpatient  68.17
Other Salmonella infections (A02); non-CSMBS outpatient  30.05
Other Salmonella infections (A02); non-CSMBS inpatient  144.74
Other Salmonella infections (A02); CSMBS outpatient  33.82
Other Salmonella infections (A02); CSMBS inpatient  162.87
Other bacterial intestinal infections (A04); non-CSMBS outpatient  26.00
Other bacterial intestinal infections (A04); non-CSMBS inpatient  125.20
Other bacterial intestinal infections (A04); CSMBS outpatient  29.25
Other bacterial intestinal infections (A04); CSMBS inpatient  140.88
Other bacterial foodborne intoxications (A05); non-CSMBS outpatient 10.27
CSMBS=Civil Servant Medical Benefit SchemeRiewpaiboon A et al. Predicting treatment cost for bacterial diarrhoea
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at the 2002 prices. At any rate, there is a substan-
tial difference between the costs of outpatient visits 
estimated by the WHO-CHOICE programme and 
that of our study (286 Thai baht vs 162 Thai baht 
respectively).
In testing the uncertainty of results due to costs of 
drugs, our study demonstrated that the effect of the 
high-priced drugs was greater than those of the fre-
quently-used drugs. This variation in prices of drugs 
is similar to that in other countries (33). Therefore, 
the results of the study indicate that management 
of drugs in Thailand should not focus solely on fre-
quently-used drugs.  
Focusing on the prediction of treatment cost-func-
tion, it is generally accepted that outpatient care 
costs less than inpatient care (34). Therefore, it 
would be interesting to explore the proportion of 
inappropriate admissions in further studies. Table 
4 presents the difference of costs due to the type 
of care for identical conditions. The differences in 
the effects of the various health insurance schemes 
could be explained by the payer-provider payment 
methods. The payment method of the primary 
insurance scheme—CSMBS—was fee-for-service 
while the other schemes were based on capitation 
methods. In the fee-for-service schemes, providers 
tend to offer more services. On the other hand, pa-
tients under the SSS incurred lower costs than those 
under the CSMBS. However, this could be an effect 
of the health-financing methods. The public hos-
pitals in Thailand receive a fixed per-capita budget 
(per person registered to the SSS). Physicians are 
urged to control expenditure with these patients. 
This phenomenon has been demonstrated in other 
studies (35-38). Similarly, the effect of insurance 
schemes on drug costs has been published in the 
United States (39). Inequity in healthcare should be 
further explored in this regard.  
The model also demonstrated the effect of patho-
gens on cost. Comparatively, other Salmonella-as-
sociated infections (ICD code A02) had the highest 
economic effect.  However, the effect of cholera, ty-
phoid, and paratyphoid fever may be inconclusive 
since a very few cases were found in the present 
study. The economic effect of pathogens was ex-
pected to relate to antimicrobial use and resistance. 
Antimicrobial resistance is an increasing problem, 
particularly in developing countries (40). Howev-
er, we did not include an antimicrobial resistance 
report of the samples in the study. A 2002 study 
reported that, in some provinces in southern Thai-
land, two major serotypes of Salmonella—Enteriti-
dis and Typhimurium—were shown to be resistant 
to tetracycline (57.1% and 83.3% respectively) and 
cefotaxime (57.1& and 50.0% respectively) (41). In 
2001, multidrug-resistant typhoid fever due to S. 
Typhi was investigated in a refugee camp, and 117 
of 294 patients showed strong adaptation and re-
mained virulent vis-a-vis streptomycin, ampicillin, 
chloramphenicol, tetracycline, and sulphamethoxa- 
zole-trimethoprim. The rate was only 10% among 
Thai patients (42).
Hospital administrators should be able to use the 
results of the present study to achieve more effec-
tive management policies. Prices of drugs in Thai-
land vary greatly. For example, the maximum price 
of norfloxacin was 13.7 times the minimum price. 
Similarly, the differences were 4.8 and 3.5 times 
for oral rehydration solution (ORS) and ciprofloxa-
cin respectively (Table 2). Therefore, costs of drugs 
could be reduced if locally-made generic drugs 
were prescribed. In addition, drug-consumption 
statistics are affected by the use of lower quanti-
ties of drugs, but at higher unit prices. This study 
demonstrated that changes in the prices of the top 
10 most frequently-used drugs reduced the costs of 
drugs by 4% while the top 10 highest-priced drugs 
raised the costs of drugs by 32%. Regarding service 
management, while other variables were assumed 
to be constant, patients under the CSMBS paid a 
higher cost/treatment rate than patients under 
other health insurance schemes. This should be a 
key concern as it violates the principle of equity in 
healthcare. In terms of infectious disease control, 
different pathogens resulted in different treatment 
costs. Investigation of pathogens among patients 
should, thus, receive more attention, and specific 
prevention measures and standard practice guide-
lines should be implemented. 
The results of this study may be limited in terms 
of generalization for the entire country since 
the data were drawn from only one hospital in 
Thailand. This is because we experienced vari-
ous constraints in including more hospitals in 
the study. Also, since Thailand did not have a 
standard cost-of-illness menu at the time of the 
study, we were required to conduct an initial 
unit-cost analysis for each hospital—a time-
consuming and expensive endeavour. Although 
the results of this study may not be applicable 
to other hospitals, they could, however, provide 
cost-conscious ideas to the Thai health ministry 
and to both practitioners and administrators of 
Thai hospitals. Lastly, others can use the results 
of the study as a basis for further research.Riewpaiboon A et al. Predicting treatment cost for bacterial diarrhoea
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In conclusion, the study found that nearly half of 
the patients with bacterial diarrhoea in Thailand 
were aged less than 15 years. Approximately half of 
them were treated as inpatients. The average es-
timated treatment cost, including cost-predicting 
variables, was US$ 45 per episode. Likewise, the effect 
of prices of drugs on treatment was explored. The 
types of service (inpatient or outpatient), pathogens, 
and health-insurance schemes significantly affected 
the predicted cost. The fitted model was able to pre-
dict greater than 80% of the treatment cost. The es-
timation of simulated patients demonstrated a wide 
range of costs, from US$ 10 per episode to US$ 163 
per episode. Overall, hospital administrators can 
apply these results in cost-containment interven-
tions.
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